Ligand Pharma (LGND) PT Raised to $262 at RBC Capital

May 8, 2026 7:34 AM

RBC Capital analyst Douglas Miehm raised the price target on Ligand Pharma (NASDAQ: LGND) to $262.00 (from $252.00) while maintaining a Outperform rating.

No results found